TAIPEI, Taiwan, December 9, 2020－TaiGen Biopharmaceuticals Holdings Limited (“TaiGen”) announced today that Phase II clinical study of influenza antiviral TG-1000 has been initiated in China. The study protocol of phase II has been approved by authorities.

The purpose of phase II study is the evaluation of effectiveness, safety and pharmacokinetics. The study design is a multi-center, randomized, double-blinded, placebo controlled and dose exploring study. About a total of 200 health volunteers are expected to be enrolled in Phase II clinical study in 30 clinical research centers.